Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Chinese EVs are good for the world. Biden says they’re bad for America. 

Why the Solomon Islands election matters to China and the U.S.

Biden calls ally Japan ‘xenophobic’ like China, Russia, at campaign event

This masterpiece ‘Birth of Venus’ probably isn’t of Venus at all

The beginner’s illustrated guide to watching an F1 race

Wait, what is Stephen A. Smith talking about? Find out with our quiz.

The 6 best things to do with kids in the D.C. area this weekend 

The 33 best things to do in D.C. this weekend and next week

Trevor Williams’s escape act helps Nationals blank Rangers 

World Press Freedom Day, 2024

How Trump convinces Republicans to adopt extreme views

Campuses are grappling with the Gaza war. So are our columnists.

Cat climbed into Amazon return box, found alive 630 miles away

Brave Little Hunter is free: Baby orca escapes lagoon for open seas

I learned to heal my sadness by cradling dying chickens 

Young Georgians want to be part of Europe. Their government is in the way.

On Press Freedom Day, little to celebrate for Hong Kong’s journalists

Taxes are inevitable. Paying to prepare them doesn’t have to be.

Stephen A. Smith would like even more of your attention

Local sports networks go dark mid-game amid dispute with Comcast 

What’s the best bus to New York? We tested 5 for comfort and value.

You asked: Do I need a passport for my cruise?

Adaptive equipment is making national parks more inclusive

That time football legend, rig-driving eligible bachelor Biden was arrested

Trump and allies say Biden pays rent for ‘illegals’ in Michigan. Not true.

Eighty percent of Ukraine-Israel bill will be spent in U.S. or by U.S. military

Miss Manners: Offering my bedroom to guests

Ask Amy: My wife’s sister confessed her feelings for me

Carolyn Hax: Will request for a postnup offend much younger wife?

NASA moon capsule suffered extensive damage during 2022 test flight

Russian state media ramping up English, Spanish presence on TikTok, study finds

Apple is behind in AI and killed its self-driving car project. What’s next?

Trump

One of the most heart-wrenching public health problems facing the world has been the large number of women who die during or after childbirth despite all our medical progress. <a href="http://www.who.int/mediacentre/events/2014/Melinda-Gates_WHA-remarks.pdf?ua=1">Melinda Gates</a> has called the issue one of her top priorities and committed more than $1.5 billion from her family’s foundation to the cause. Countless scientists have explored the issue from every angle.

But could part of the solution be simpler than we imagined?

The results of a remarkable clinical trial released Wednesday in the journal <a href="http://www.thelancet.com/journals/lancet/article/piis0140-6736(17)30638-4/fulltext?elsca1=tlpr)">Lancet</a> suggest that a single injection of an old drug — and one that costs less than $1 a dose — may be able to save tens of thousands of lives each year.

The study, conducted in 193 hospitals in 21 countries, involved 20,000 women who were undergoing one of the most life-threatening medical complications: postpartum hemorrhage. Giving birth takes a brutal toll on a woman's body, and many things can go wrong along the way — a tear in the vagina or birth canal, a rupture of the cervix, a placenta that is stuck to the womb and doesn't separate properly. In some cases, women experience a coagulation problem in which there is no obvious injury but there is uncontrollable bleeding. This bleeding is the leading cause of maternal mortality around the world. An estimated 14 million women experience postpartum hemorrhage, and more than 100,000 die from it per year.

In the study, known as the WOMAN (or World Maternal Antifibrinolytic) Trial, patients were randomized to receive either a placebo or tranexamic acid (TXA), which helps the blood to clot. The treatment, given intravenously, was used alongside other actions that emergency doctors would normally take to try to stop such bleeding. The trial was double-blind, meaning neither the doctors and researchers nor the patients knew what they got.

<span style="line-height: 1.5;">In analyzing the outcomes of the women, the research team, co-led by the London School of Hygiene and Tropical Medicine’s Ian Roberts, found that the risk of death from bleeding was reduced by 20 percent for the women who got tranexamic compared with those who got nothing. If the medicine was given quickly, within three hours of the start of bleeding, the results were even more promising — with a 30 percent reduction in the risk of death.</span>

TXA was discovered more than 50 years ago by a Japanese doctor, Utako Okamoto, but TXA's value wasn’t recognized until relatively recently. In 2010, another large trial — known as CRASH-2 — that involved victims of traffic accidents, shootings and land mines who were bleeding out showed that TXA could reduce the risk of death in those trauma patients by 15 percent.

Paramedics in some countries carry the injection, and the World Health Organization has added it to its list of essential medicines that should be available to everyone and that form the basis of national drug policy in countries across the world.

Roberts, who also worked on the trauma trial, said TXA's under-appreciation for so long underscores how the global system of pharmaceutical discovery and development is broken. If it wasn’t for Gates and other donors like the Wellcome Trust getting involved and funding the postpartum-bleeding trial, it may have never gotten off the ground.

“There has been a market failure with this drug for a long time,” Roberts said. “We didn’t reap its humanitarian benefit because there was no sort of financial incentive to do so.”

Wellcome Trust senior partner Tim Knott said the trial “stands to make a critical difference in preventing women dying after childbirth.”

Not only is TXA cheap, it doesn’t need to be refrigerated, making it easy to transport and store. The main drawback, Roberts said, is that many women in the developing world give birth in remote areas assisted only by a midwife or someone else who may not be trained to give an intravenous injection. He said the researchers' next step is to look at formulations of TXA that can have a similar effect but can be given in pill or other form so someone with little training can administer it.

The WHO recommends that TXA be given if other efforts to control bleeding fail, but Roberts said the study suggests that the timeline for the drug be accelerated, especially in developing countries, so that doctors give it as soon as the bleeding begins.

“The trial data show women die really soon after onset,” he said. “If a woman has a postpartum hemorrhage in Washington, D.C., the hospital will likely have a lot of blood in the blood bank and lots of tools to keep a woman stable while they try one thing and then another. But in Africa, a woman can die within the hour or certainly within that day if the bleeding is not controlled."

Columbia University

Ariana Eunjung Cha is a national reporter. She has previously served as The Post's bureau chief in Shanghai and San Francisco, and as a correspondent in Baghdad.

Ariana Eunjung Cha

The Washington Post

Health Care

Medical Mysteries

Science

Well+Being

Health

prism://prism.query/site,/health&limit=20

The Washington Post health section provides coverage and analysis of health, healthcare, nutrition and fitness news.